2024 SABCS Meeting Magazine - 11

DECEMBER 11 (ALL TIMES ARE IN CENTRAL STANDARD TIME)
* Novel Imaging Modalities
Connie Lehman, Harvard
Medical School and
Massachusetts General
Hospital, Boston,
Massachusetts
* Screening for High-Risk
Women
Speaker to be announced
* Panel Discussion
12:30 - 2:00 p.m.
Poster Session 1
HALLS 2-3
1:00 - 1:50 p.m.
Clinical Case Discussions
STARS AT NIGHT 1-2
Moderator: Debra Patt, Texas
Oncology, Austin, Texas
Patient Advocate: Kelly Shanahan,
Tahoe, California
* Sonya Reid, Vanderbilt Ingram
Cancer Center, Nashville,
Tennessee
* Icro Meattini, Florence
University Hospital, Florence,
Italy
* Tari King, Dana-Farber
Cancer Institute, Boston,
Massachusetts
* Joannie Ivory, UNC Lineberger
Comprehensive Cancer Center,
Chapel Hill, North Carolina
* Anne Salomon, Institut Curie,
Paris, France
* Harold Burstein, Dana-Farber
Cancer Institute, Boston,
Massachusetts
1:00 - 3:30 p.m.
Navigating Success: Women's
Career Development
ROOM 221 ABC
Moderator: Anne Welsh,
Psychologist and Executive Coach,
Cambridge, Massachusetts
* Setting The Stage For Success
Anne Welsh, Psychologist and
Executive Coach, Cambridge,
Massachusetts
* Evidence-Based Strategies
To Address Systemic
Barriers Facing Women
Researchers
Reshma Jagsi, Emory
University, Atlanta, Georgia
2:00 - 3:00 p.m.
State of the Art Session 1:
The Winding Road of Immune
Biomarkers in Early Breast
Cancer
STARS AT NIGHT 3-4
Moderator: Sherene Loi, Peter
MacCallum Cancer Centre,
Melbourne, Australia
* TILs: An Update After 10
Years of Research
Roberto Salgado, Peter
MacCallum Cancer Centre,
Melbourne, Australia
* Immune Biomarkers
Beyond TILs
Justin Balko, VanderbiltIngram
Cancer Center,
Nashville, Tennessee
* Deploying Immune
Biomarkers in Clinical Trials
Priyanka Sharma, University
of Kansas Medical Center,
Westwood, Kansas
* Panel Discussion
Translational Controversies
STARS AT NIGHT 1-2
Moderator: Antonio Wolff, Johns
Hopkins University, Baltimore,
Maryland
* How to Define Triple
Negative Breast Cancer
Rebecca Dent, National
Cancer Center Singapore,
Singapore
Charles Perou, UNC Lineberger
Comprehensive Cancer Center,
Chapel Hill, North Carolina
* Tumor Agnostic Drug
Development
Funda Meric-Bernstam, MD
Anderson Cancer Center,
Houston, Texas
Fabrice Andre, Institut Gustave
Roussy, Villejuif, France
3:00 - 3:30 p.m.
AACR Outstanding
Investigator Award for Breast
Cancer Research
STARS AT NIGHT 1-2
3:30 - 5:15 p.m.
Educational Session 5:
Unlocking New Targets with
Molecular Degraders
HEMISFAIR BALLROOM 3
December 10-13, 2024 | San Antonio, Texas
Moderator: Carlos Arteaga, UT
Southwestern Medical Center,
Dallas, Texas
* PROTACs
Stephen Hinshaw, Stanford
Cancer Institute, Palo Alto,
California
* Lysosome-targeting Chimeras
Speaker to be announced
* Biparatopic Antibodies
Saireudee Chaturantabut,
Broad Institute of MIT
and Harvard, Cambridge,
Massachusetts
* Panel Discussion
*
Educational Session 6: Case
Based Clinical Approach
to ER Positive Metastatic
Breast Cancer - In honor of Dr.
V. Craig Jordan
STARS AT NIGHT 1-2
Moderators: William Gradishar,
Northwestern University Feinberg
School of Medicine, Chicago, Illinois
and Sara Hurvitz, Fred Hutch Cancer
Center, Seattle, Washington
Case Presentations and Discussants:
Michael Oliphant, Harvard Medical
School, Boston, Massachusetts
Marla Lipsyc-Sharf, UCLA Health,
Santa Monica, California
Neil Vasan, Columbia University
Irving Medical Center, New York,
New York
Dan Stover, The Ohio State
University Comprehensive Cancer
Center, Columbus, Ohio
Amy Beumer, Patient Advocate,
Mason, Ohio
* Case 1: New diagnosis
ER+HER2-MBC: genomic
considerations
* Case 2: Can we delay
CDK4/6i treatment until the
second line?
* Case 3: Selecting therapy after
progression of disease on
CDK4/6i therapy in patients
with PI3K pathway mutations
* Case 4: Selecting treatment
for patient with tumor ESR1
mutation
* Case 5: When it's time to
move on from endocrine
approaches, chemo or ADC?
Education Session 7: People's
Choice - Future Directions in
Antibody Drug Conjugates
HEMISFAIR BALLROOM 1-2
Wednesday
Moderator: Paolo Tarantino, DanaFarber
Cancer Institute, Boston,
Massachusetts
* The ABC of ADCs: history,
mechanism of action,
mechanisms of resistance
John Lambert, John Lambert
Consulting, Cambridge,
Massachusetts
* Treating breast cancer
with ADCs: clinical role and
emerging challenge.
Giuseppe Curigliano,
European Institute of
Oncology, Milan, Italy
The art of developing ADCs:
insights at the intersection
of academia and industry.
Ingrid Mayer, AstraZeneca,
Frederick, Maryland
*
Aiming for the target:
Increasing the precision
of ADCs through novel
biomarkers and innovative
molecular constructs.
Paolo Tarantino, Dana-Farber
Cancer Institute, Boston,
Massachusetts
Educational Session 8:
Optimizing Local Therapy
STARS AT NIGHT 3-4
Moderator: Tari King, Dana-Farber
Brigham Cancer Center, Boston,
Massachusetts
Patient Advocate: Yvonne Florance,
Philadelphia, Pennsylvania
* Let's Talk About PBI
Atif Khan, Memorial Sloan
Kettering Cancer Center, New
York, New York
* Axillary Management: When
to Dissect and When to
Radiate
Stephanie Wong, Jewish
General Hospital Segal
Cancer Centre, McGill
University Medical School,
Montreal, Canada
* Surgical Prevention
and Management of
Lymphedema
Sarah McLaughlin, Mayo
Clinic, Jacksonville, Florida
* Panel Discussion
5:30 - 7:00 p.m.
Poster Session 2
HALLS 2-3
11
2024 SABCS Meeting Magazine

Table of Contents for the Digital Edition of 2024 SABCS Meeting Magazine
